4.08
-0.15(-3.55%)
Currency In USD
| Previous Close | 4.23 |
| Open | 4.21 |
| Day High | 4.21 |
| Day Low | 4.01 |
| 52-Week High | 7.08 |
| 52-Week Low | 2.61 |
| Volume | 612,854 |
| Average Volume | 1.84M |
| Market Cap | 517.8M |
| PE | -51 |
| EPS | -0.08 |
| Moving Average 50 Days | 5.08 |
| Moving Average 200 Days | 4.41 |
| Change | -0.15 |
If you invested $1000 in Organogenesis Holdings Inc. (ORGO) since IPO date, it would be worth $418.46 as of January 14, 2026 at a share price of $4.08. Whereas If you bought $1000 worth of Organogenesis Holdings Inc. (ORGO) shares 5 years ago, it would be worth $429.93 as of January 14, 2026 at a share price of $4.08.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Organogenesis Announces Initiation of Biologics License Application for ReNu®
GlobeNewswire Inc.
Dec 23, 2025 9:05 PM GMT
Initial modules submitted to FDA under rolling review; final modules expected in the first half of 2026CANTON, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on t
Organogenesis Announces Successful FDA Meeting and Plan to File BLA for ReNu® for Knee Osteoarthritis Pain
GlobeNewswire Inc.
Dec 15, 2025 9:25 PM GMT
Clinical Development Program Appropriate for Rolling BLA Submission Expected by the End of 2025 CANTON, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the dev
Organogenesis Applauds CMS’s Significant Step In Payment Reform
GlobeNewswire Inc.
Nov 03, 2025 6:10 PM GMT
With evidence-based portfolio including technologies in each FDA category, we believe we are best positioned in the skin substitutes market for 2026 and beyondCANTON, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORG